Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Sequential Ad5-nCoV Booster in Elderly Chinese Adults Primed with Inactivated COVID-19 Vaccine
NCT04952727Phase 4Completed
- Sponsor
- Jiangsu Provincial Center for Disease Control and Prevention
- Start
- Aug 2021
- Primary completion
- Nov 2021
- Modality
- Viral Vectors, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of ad5-ncov in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by Jiangsu Provincial Center for Disease Control and Prevention. Primary endpoints: Incidence of adverse reactions at 28 days and Geometric Mean Titer (GMT) of neutralizing antibodies against live SARS-CoV-2 virus at 14 days. Started Aug 2021; status: completed.
02
Drugs
ad5-ncov
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04952727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04952727.